Effect of treatment and mammography detection on breast cancer survival over time: 1990-2007

Cancer

Volumn 121, Issue 15, 2015, Pages 2553-2561

  Kaplan, Henry G ^a   Malmgren, Judith A ^b,c   Atwood, Mary K ^a   Calip, Gregory S ^d  

^a SWEDISH MEDICAL CENTER   (United States)

^b HealthStat Consulting   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

adjuvant chemotherapy; breast cancer; mammography; regression modeling; survival

Indexed keywords

AGED; BREAST NEOPLASMS; CANCER REGISTRY; EPIDEMIOLOGY; FEMALE; HUMAN; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; MORTALITY; RADIOGRAPHY; RETROSPECTIVE STUDY; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA; SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS; UNITED STATES;

AGED; BREAST NEOPLASMS; FEMALE; HUMANS; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; RETROSPECTIVE STUDIES; SEER PROGRAM; SOCIOECONOMIC FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 84937525800     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29371     Document Type: Article

References (39)

1. DeSantis C, Ma J, Bryan L, Jemal A,. Breast cancer statistics 2013. CA Cancer J Clin. 2014; 64: 52-63.
2. Berry DA, Cronin KA, Plevritis SK, et al., Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005; 353: 1784-1792.
3. Mandelblatt J, van Ravesteyn N, Schechter C, et al., Which strategies reduce breast cancer mortality most? Collaborative modeling of optimal screening, treatment and obesity prevention. Cancer. 2013; 119: 2541-2548.
4. Kalager M, Zelen M, Langmark F, Adami HO,. Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med. 2010; 363: 1203-1210.
5. Marmot MG,. Sorting through the arguments on breast screening. JAMA. 2013; 309: 2553-2554.
6. Jatoi I,. The impact of advances in treatment on the efficacy of mammography screening. Prev Med. 2011; 53: 103-104.
7. Bleyer A, Welch HG,. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012; 367: 1998-2005.
8. American Cancer Society. Chronological history of ACS recommendations for the early detection of cancer in people without cancer symptoms. Available at: http://www.cancer.org/healthy/findcancerearly/cancerscreeningguidelines/chronological-history-of-acs-recommendations. Accessed March 26, 2014.
9. Woolf SH,. United States Preventive Services Task Force recommendations on breast cancer screening. Cancer. 1992; 69 (7 suppl): 1913-1918.
10. Von Euler-Chelpin M, Lynge E, Reboli M,. Register-based studies of cancer screening effects. Scand J Public Health. 2011; 39 (7 suppl): 158-164.
11. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 2.2014. Fort Washington, PA: National Comprehensive Care Network, Inc.; 2014. Available at: http://www.nccn.org/professionals/physician-gls/pdf/breast.pdf. Accessed March 25, 2014.
12. US Preventive Services Task Force. Screening for breast cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009; 151: 716-726.
13. Edge SB, Burd DR, Compton CC, et al, eds. AJCC Cancer Staging Manual. 7th ed. New York: Springer-Verlag; 2010.
14. Cancer Surveillance System of the Fred Hutchinson Cancer Research Center, contract No. N01-CN-67009. Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute, Bethesda, Md.
15. IBM Corporation. IBM SPSS Statistics for Windows, version 21.0 [software program]. Armonk, NY: IBM Corporation; 2012.
16. StatCorp LP,. Stata/IC Statistical Software, version 13 [software program]. College Station, TX: StataCorp LP; 2013.
17. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2008; based on the November 2012 SEER data submission, posted to the SEER web site. Bethesda, MD: National Cancer Institute; 2012. Available at: http://seer.cancer.gov/csr/1975-2008/. Accessed January 27, 2014.
18. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov). SEER Stat Database: Incidence-SEER 18 Regs Research Data, Nov 2013 Submission (1973-2011) -Linked to County Attributes-Total US, 1969-2012 Counties. Bethesda, MD: National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch; 2013.
19. Cho H, Howlader N, Mariotto AB, Cronin KA,. Estimating relative survival for cancer patients from the SEER Program using expected rates based on Ederer I versus Ederer II method. Technical Report 2011-01. Bethesda, MD: Surveillance Research Program, National Cancer Institute; 2011. Available at: http://surveillance.cancer.gov/reports/tech2011.01.pdf. Accessed April 1, 2015.
20. Ederer F, Axtell LM, Cutler SJ,. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr. 1961; 6: 101-121.
21. Henderson IC, Berry DA, Demetri GD, et al., Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003; 21: 976-983.
22. Mamounas EP, Bryant J, Lembersky B, et al., Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005; 23: 3686-3696.
23. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med. 1988; 319: 1681-1692.
24. Tamoxifen for early breast cancer: an overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998; 351: 1451-1167.
25. Heimann R, Munsell M, McBride R,. Mammographically detected breast cancers and the risk of axillary lymph node involvement: is it just the tumor size? Cancer J. 2002; 8: 276-281.
26. Drukker CA, Schmidt MK, Rutgers EJ, et al., Mammographic screening detects low-risk tumor biology breast cancers. Breast Cancer Res Treat. 2014; 144: 103-111.
27. Malmgren JA, Parikh J, Atwood MK, Kaplan HG,. Impact of mammography detection on the course of breast cancer in women aged 40-49 years. Radiology. 2012; 262: 797-806.
28. National Cancer Institute. The Surveillance, Epidemiology, and End Results (SEER) Cancer Statistics Review 1975-2007. Bethesda, MD: National Cancer Institute; 2012.
29. National Center for Health Statistics. Health, United States, 2013: With Special Feature on Prescription Drugs. Hyattsville, MD; 2014. Available at; http://www.cdc.gov/nchs/data/hus/hus13.pdf. Accessed December 15, 2014.
30. van Schoor G, Moss SM, Otten JD, et al., Increasingly strong reduction in breast cancer mortality due to screening. Br J Cancer. 2011; 104: 910-914.
31. Molinie F, Vanier A, Woronoff AS, et al., Trends in breast cancer incidence and mortality in France 1990-2008. Breast Cancer Res Treat. 2014; 147: 167-175.
32. Pisani P, Forman D,. Declining mortality from breast cancer in Yorkshire, 1983-1998: extent and causes. Br J Cancer. 2004; 90: 652-656.
33. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, et al., Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomized trials. Lancet. 2011; 378: 1707-1716.
34. Agarwal S, Pappas L, Neumayer L, Kokeny K, Agarwal J,. Effect of breast conservation therapy versus mastectomy on disease-specific survival for early-stage breast cancer. JAMA Surg. 2014; 149: 267-274.
35. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL,. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235: 177-182.
36. Cobleigh MA, Vogel CL, Tripathy D, et al., Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressng metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999; 17: 2639-2648.
37. Owens MA, Horten BC, Da Silva MM,. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004; 5: 63-69.
38. Yaziji H, Goldstein LC, Barry TC, et al., HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004; 291: 1972-1927.
39. Elkin EB, Ishill NM, Snow JG, et al., Geographic access and the use of screening mammography. Med Care. 2010; 48: 349-356.